DOCSLIB.ORG

Comparison Between Morphine and Morphine Plus Ketamine for Postoperative Pain Relief After Orthopaedic Surgery

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comparison Between Morphine and Morphine Plus Ketamine for Postoperative Pain Relief After Orthopaedic Surgery Ο University of Khartoum Faculty of Medicine Postgraduate Medical Studies Board Comparison between Morphine and Morphine plus Ketamine for postoperative pain relief after orthopaedic surgery By Dr. Sarah Mahmoud Nuri M.B.B.S, (University of Khartoum) A thesis submitted in partial fulfilment for the requirements of the degree of Clinical MD in anaesthesia & intensive care, May 2004 Supervisor Prof. Ali Ahmed Salama MBBS, DA, FFA Faculty of Medicine Neelain University To my mother ...... My grateful acknowledgement is made to Dr. Ali Ahmed Salama for his supervision, encouragement, and advice during the performance of this study. I'm also grateful to all orthopaedic registrars and house officers who helped me in collecting the data. I’m also grateful to Dr. Yassir Salih for his great help and support. I would like also to thank my family for their help and support. LIST OF ABBREVIATIONS CAMP Cyclic adenosine mono phosphate. PIP2 Phosphatidyl inositol di phosphate. IP3 Inositol tri phosphate. ADH Anti Diuretic Hormone. GF Glumerular Filtration. BP Blood Pressure. ECG Electro cadiogram. CBF Cerebral Blood Flow GI Gastro Intestinal CNS Central Nervous system ASA American Society of Anesthiologist VAS Visual analogue scale. NSAIDs Non steroidal anti infalammatory drugs. NMDA N-methyl- D- Aspartate GFR Glumerular filtration rate. EEG Electroencephalogram. ABSTRACT The aim of this study is detection of the efficacy of ketamine in low doses as a potent analgesic and it's ability to provide superior analgesia when added to morphine. It compared morphine with ketamine to morphine alone in Quasi experimental design of post surgical pain control . Also this study compared the incidence of morphine common side effects between the two groups. Eighty ASA class I and II patients undergoing elective orthopaedic surgery were administered either 10 mg of morphine \ 8 hourly or 10 mg of morphine plus 0.5 mg/ kg ketamine 8 hourly via intravenous route, pain relief and side effects were assessed 24 hours after surgery. The mean visual analogue scale (VAS) pain rating of patients receiving morphine with ketamine was lower than the (VAS) scores of patients receiving only morphine. There was no much difference in side effects between the two groups, they reported the same incidence of nausea, pruritis and urinary retention. There was higher incidence of dysphoria in morphine plus ketamine group but they reported a lower incidence of sedation. In conclusion I/V ketamine in combination with morphine provide superior post surgical pain relieve. ﻤﻠﺨﺹ ﺍﻷﻁﺭﻭﺤﺔ ﺍﻟﻬﺩﻑ ﻤﻥ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺘﻘﻴﻴﻡ ﻓﻌﺎﻟﻴﺔ ﻋﻘﺎﺭ ﺍﻟﻜﺘﺎﻤﻴﻥ ﻓﻰ ﺠﺭﻋﺎﺕ ﺼﻐﻴﺭﺓ ﻜﻤﺅﺜﺭ ﻗﻭﻱ ﻟﺘﺴﻜﻴﻥ ﺍﻵﻻﻡ ﻭﻤﻘﺩﺭﺘﻪ ﻹﺤﺩﺍﺙ ﺘﺄﺜﻴﺭ ﺃﻗﻭﻯ ﻋﻨﺩ ﺇﻀﺎﻓﺘﻪ ﻟﻌﻘﺎﺭ ﺍﻟﻤﻭﺭﻓﻴﻥ. هﺬﻩ اﻟﺪراﺳﺔ اﻟﺘﺠﺮﻳﺒﻴﺔ أﺟﺮﻳﺖ ﻟﻤﻘﺎرﻧﺔ ﻣﻔﻌﻮل اﻟﻤﻮرﻓﻴﻦ وﻣﻔﻌﻮل اﻟﻤﻮرﻓﻴﻦ ﻣﻊ اﻟﻜﺘﺎﻣﻴﻦ ﻟﺘﺴﻜﻴﻦ ﺁﻻم ﻣﺎ ﺑﻌﺪ اﻟﻌﻤﻠﻴﺎت اﻟﺠﺮاﺣﻴﺔ. آﻤﺎ ﻗﺎرﻧﺖ هﺬﻩ اﻟﺪراﺳﺔ اﻵﺛﺎر اﻟﺠﺎﻧﺒﻴﺔ اﻟﻨﺎﺗﺠﺔ ﻣﻦ ﻋﻘﺎر اﻟﻤﻮرﻓﻴﻦ ﻓﻰ آﻼ اﻟﻤﺠﻤﻮﻋﺘﻴﻦ. إﺷﺘﻤﻠﺖ هﺬﻩ اﻟﺪراﺳﺔ ﻋﻠﻰ 80 ﻣﺮﻳﺾ ﻓﻰ ﻗﺴﻢ ﺟﺮاﺣﺔ اﻟﻌﻈﺎم ﻣﻦ اﻟﻤﺠﻤﻮﻋﺔ اﻷوﻟﻰ واﻟﺜﺎﻧﻴﺔ ﺗ ﺒ ﻌ ﺎً ﻟﺘﺼﻨﻴﻒ اﻟﺠﻤﻌﻴﺔ اﻷﻣﺮﻳﻜﻴﺔ ﻹﺧﺘﺼﺎﺻﻲ اﻟﺘﺨﺪﻳﺮ. وﺗﻢ ﺗﻘﺴﻴﻢ اﻟﻤﺮﺿﻰ ﻟﻤﺠﻤﻮﻋﺘﻴﻦ. أﻋﻄﻴﺖ اﻟﻤﺠﻤﻮﻋﺔ اﻷوﻟﻰ ﻋﻘﺎر اﻟﻤﻮرﻓﻴﺖ(10 ﻣﻠﺠﻢ ﺑﺎﻟﻮرﻳﺪ آﻞ 8 ﺳﺎﻋﺎت) واﻟﻤﺠﻤﻮﻋﺔ اﻟﺜﺎﻧﻴﺔ أﻋﻄﻴﺚ ﻋﻘﺎر اﻟﻤﻮرﻓﻴﻦ زاﺋﺪ اﻟﻜﺘﺎﻣﻴﻦ (10ﻣﺞ ﻣﻮرﻓﻴﻦ + 0.5 ﻣﺞ آﺘﺎﻣﻴﻦ ﻟﻜﻞ آﺠﻢ ﻣﻦ وزن اﻟﻤﺮﻳﺾ آﻞ 8 ﺳﺎﻋﺎت) ﺑﺎﻟﻮرﻳﺪ وﻗﺪ ﺗﻢ ﺗﻘﻴﻴﻢ اﻷﻟﻢ واﻵﺛﺎر اﻟﺠﺎﻧﺒﻴﺔ ﻟﻠﻤﺮﺿﻰ ﻓﻰ اﻟﻤﺠﻤﻮﻋﺘﻴﻦ ﺑﻌﺪ 24 ﺳﺎﻋﺔ. أﺛﺒﺘﺖ هﺬﻩ اﻟﺪراﺳﺔ أن ﻋﻘﺎر اﻟﻤﻮرﻓﻴﻦ زاﺋﺪ اﻟﻜﺘﺎﻣﻴﻦ ذو ﻓﻌﺎﻟﻴﺔ أﻗﻮى ﻋﻠﻰ إزاﻟﺔ اﻷﻟﻢ ﻣﻦ ﻋﻘﺎر اﻟﻤﻮرﻓﻴﻦ وﻻ ﻳﻮﺟﺪ إﺧﺘﻼف آﺒﻴﺮ ﺑﻴﻦ اﻵﺛﺎر اﻟﺠﺎﻧﺒﻴﺔ ﻟﻠﻤﻮرﻓﻴﻦ ﺑﻴﻦ اﻟﻤﺠﻤﻮﻋﺘﻴﻦ ﺣﻴﺚ أن ﻣﻌﺪل اﻹﺳﺘﻘﻴﺎء واﻟﻬﺮش اﻟﺠﻠﺪي واﻟﺤﺒﺲ اﻟﺒﻮﻟﻲ آﺎن ﻣﺘﺴﺎوﻳﺎً ﺑﻴﻦ اﻟﻤﺠﻤﻮﻋﺘﻴﻦ. اﻣﺎ ﻣﻌﺪل اﻟﻬﻠﻮﺳﺔ ﻓﻜﺎن أﻋﻠﻰ ﻓﻰ اﻟﻤﺠﻤﻮﻋﺔ اﻟﺘﻰ أﻋﻄﻴﺖ ﻋﻘﺎر اﻟﻤﻮرﻓﻴﻦ زاﺋﺪ اﻟﻜﺘﺎﻣﻴﻦ وﻣﻌﺪل اﻻﺳﺘﺮﺧﺎء آﺎن أﻗﻞ ﻓﻰ اﻟﻤﺠﻤﻮﻋﺔ اﻟﺘﻰ أﻋﻄﻴﺖ ﻋﻘﺎر اﻟﻤﻮرﻓﻴﻦ زاﺋﺪ اﻟﻜﺘﺎﻣﻴﻦ. LIST OF FIGURES Page Fig. 1: Age distribution (morphine group) 43 Fig. 2: Age distribution (morphine + katamine group) 44 Fig. 3: Sex distribution (morphine group) 45 Fig. 4: Sex distribution (morphine + katamine group) 46 LIST OF TABLES Page Table 1: Mean score of dysphoria reported by patients receiving morphine or morphine plus ketamine 47 Table 2: Mean score of nausea reported by patients receiving morphine or morphine plus ketamine 48 Table 3: Mean score of pruritis reported by patients receiving morphine or morphine plus ketamine 49 Table 4: Mean score of sedation reported by patients receiving morphine or morphine plus ketamine 50 Table 5: Mean score of urine retention reported by patients receiving morphine or morphine plus ketamine 51 Table 6: Mean score of pain reported by patients receiving morphine or morphine plus ketamine 52 CONTENTS Page Dedication……………………………………………………………......I Acknowledgements……………………………………………...….....II Abbreviations …………………………………………….……….…...III English abstract ……………………………………………………...IV Arabic abstract ……………………………….....……………..…...VI List of tables …………..…..……………. …................…...…....….VII List of figures ………..………..…….……. ……................…....….VIII CHAPTER ONE Introduction ………………………………………………….……...….1 Literature review……………………………….…………….........…...6 Objectives…………………………………………………………......35 CHAPTER TWO Patients and Methods …………………………………..……....……36 CHAPTER THREE Results ………………………………………………………………..40 CHAPTER FOUR Discussion…………………………………...…………………………53 Conclusion ………………………………...……………………….…58 Recommandations …………………………………………...…..…..59 References ………………………………………………………...….60 Appendix (questionnaire)……………………………………………68 INTRODUCTION Why it's important to treat postoperative pain? Apart from the obvious humanitarian reasons for relieving unnecessary suffering from acute severe pain, pain relieve is a prerequisite for an active rehabilitation regimen after surgery. There is a number of potentially beneficial effects on the post operative course of optimal post operative pain relief. These include: Improved pulmonary function. Improved cardiovascular function. Improved gastrointestinal function. Fewer thromboembolic complications. Reduced mortality in high-risk patients. Improved postoperative metabolism. Fewer septic complications. Shorter convalescence after surgery. Reduced chronic post surgical pain. Improved arterial graft survival. Reduced health care costs.(1) Why there is a poor control of postoperative pain?: An editorial in the British Medical Journal in 1978 stated: (it’s an indictment of modern medicine that an apparently simple problem such as the relief of post operative pain remains largely unsolved).(2) What can anaesthetist do to prevent postoperative pain?: 1- Pre-emptive analgesia: Experimentally, it has been shown that nociceptive stimulation from the periphery, causes functional changes in the spinal cord which lead to enhancement and prolongation of the sensation of pain. It has also been shown that prior administration of analgesics may inhibit the development of the hyper excitability within the spinal cord. Unfortunately, however, in clinical practice, prior administration of analgesics (pre-emptive analgesia) has not been shown to have an important effect on postoperative pain.(3) 2- Relief of postoperative pain in the post anaesthesia period: Balanced analgesia: The principle of balanced analgesia regimen is to combine several therapeutic modalities to optimize pain relief, while minimizing unwanted effects.(4) First: For short term use NSAID: They seem largely safe, provided that, the patient has no history of allergy to any of the drugs, GI ulcers, bleeding problems, hypovolaemia or reduced renal function. Paracetamol is the safest drug in this category. Second: use regional or local analgesia whenever appropriate: For major abdominal, thoracic and orthopedic surgery the most effective method of relieving severe pain in the immediate post anesthetic period is by prolonging a segmental epidural analgesia used as part of an operative anaesthetic technique. A number of peripheral nerve blocks are very useful. Wound infiltration with local anesthetic solution can also be quite effective. Third: add an opioid analgesic. For immediate post anaesthesia period, an opioid analgesic will usually be needed for an optimal pain relief, in the majority of patients after surgery. This can be administered in the traditional way. After more extensive surgery three alternative regimens for opioid administration may have advantages: a. Nurse controlled continuous opioid infusion analgesia. b. Patient controlled intravenous opiod analgesia. c. Epidural analgesia with an opiod drug combined with low dose local anesthetic drug. Nurse controlled continuous opioid infusion analgesia: This technique is employed to provide analgesia in patients receiving artificial ventilation in intensive therapy unit (ITU). It has also been used in general surgical wards for provision of postoperative analgesia in spontaneously breathing patients. The dose rate is determined by the nurse on trial and error basis and a fixed infusion rate prescribed. However this carries great risk of producing ventilatory depression and can not be recommended in spontaneously breathing patients outside a high dependency unit or intensive therapy unit. Patient controlled opioid analgesia (PCA): The basis for controlled intravenous opioid analgesia is that the patient can best evaluate pain and pain relief, by this technique the problems of the fluctuation in intensity of postoperative pain, the variable pain sensitivity, and the variable pharmacokinetics of opioids between patients will be solved. Optimally balanced epidural analgesia: Choice of drug combination: It’s now well established that specific spinal analgesia can be obtained clinically by at least three separate mechanisms
Load more

Recommended publications
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence
    National Institute on Drug Abuse MONOGRAPH SERIES Problems of Drug Dependence 1980 Proceedings of the 42nd Annual Scientific Meeting The Committee on Problems of Drug Dependence, Inc. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Problems of Drug Dependence, 1980 Proceedings of the 42nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Editor: Louis S. Harris, Ph.D. NIDA Research Monograph 34 February 1981 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University, New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Deportment of Psychology, UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHHS Washington, D.C Lee Robins, Ph.D.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday Et Al
    US 20110245287A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday et al. (43) Pub. Date: Oct. 6, 2011 (54) HYBRD OPOD COMPOUNDS AND Publication Classification COMPOSITIONS (51) Int. Cl. A6II 3/4748 (2006.01) C07D 489/02 (2006.01) (76) Inventors: John W. Holaday, Bethesda, MD A6IP 25/04 (2006.01) (US); Philip Magistro, Randolph, (52) U.S. Cl. ........................................... 514/282:546/45 NJ (US) (57) ABSTRACT Disclosed are hybrid opioid compounds, mixed opioid salts, (21) Appl. No.: 13/024,298 compositions comprising the hybrid opioid compounds and mixed opioid salts, and methods of use thereof. More particu larly, in one aspect the hybrid opioid compound includes at (22) Filed: Feb. 9, 2011 least two opioid compounds that are covalently bonded to a linker moiety. In another aspect, the hybrid opioid compound relates to mixed opioid salts comprising at least two different Related U.S. Application Data opioid compounds or an opioid compound and a different active agent. Also disclosed are pharmaceutical composi (60) Provisional application No. 61/302,657, filed on Feb. tions, as well as to methods of treating pain in humans using 9, 2010. the hybrid compounds and mixed opioid salts. Patent Application Publication Oct. 6, 2011 Sheet 1 of 3 US 2011/0245287 A1 Oral antinociception of morphine, oxycodone and prodrug combinations in CD1 mice s Tigkg -- Morphine (2.80 mg/kg (1.95 - 4.02, 30' peak time -- (Oxycodone (1.93 mg/kg (1.33 - 2,65)) 30 peak time -- Oxy. Mor (1:1) (4.84 mg/kg (3.60 - 8.50) 60 peak tire --MLN 2-3 peak, effect at a hors 24% with closes at 2.5 art to rigg - D - MLN 2-45 (6.60 mg/kg (5.12 - 8.51)} 60 peak time Figure 1.
    [Show full text]
  • WO 2012/109445 Al 16 August 2012 (16.08.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/109445 Al 16 August 2012 (16.08.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/485 (2006.01) A61P 25/04 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US20 12/024482 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (22) International Filing Date: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, ' February 2012 (09.02.2012) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 13/024,298 9 February 201 1 (09.02.201 1) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): QRX- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, PHARMA LTD.
    [Show full text]
  • ATP, 489 Absolute Configuration Benzomotphans, 204 Levotphanol
    Index AIDA, 495 Affinity labeling, analogs of (Cont.) cAMP, 409, 489 motphine,448 ATP, 409, 489 naltrexone, 449 [3H] ATP, 489 norlevotphanol,449 Absolute configuration normetazocine, 181 benzomotphans, 204 norpethidine, 232 levotphanol, 115 oripavine, 453 methadone and analogs, 316 oxymotphone, 449 motphine, 86 K-Agonists, 179,405,434 phenoperidine, 234 Aid in Interactive Drug Analysis, 495 piperazine derivatives, 399 [L-Ala2] dermotphin, 363 prodines and analogs, 272 [D-Ala, D-Leu] enkephalin (DADL), 68, 344 sinomenine, 28, 115 [D-Ala2 , Bugs] enkephalinamide, 347, 447 viminol, 400 [D-Ala2, Met'] enkephalinamide, 337, 346, Ac 61-91,360 371,489 Acetylcholine, 5, 407 [D-Ala2]leu-enkephalin, 344, 346, 348 Acetylcholine analogs, 186, 191 [D-Ala2] met-enkephalin, 348 l-Acetylcodeine, 32 [D-Ala2] enkephalins, 347 Acetylmethadols (a and (3) Alfentanil, 296 maintenance of addicts by a-isomer, 304, 309 (±)-I1(3-Alkylbenzomotphans, 167, 170 metabolism, 309 11(3-Alkylbenzomotphans, 204 N-allyl and N-CPM analogs, 310, 431 7-Alkylisomotphinans, 146 stereochemistry, 323 N-Alkylnorketobemidones, 431 synthesis, 309 N-Alkylnorpethidines, 233 X-ray crystallography, 327 N-Allylnormetazocine, 420 6-Acetylmotphine, receptor binding, 27 N-Allylnormotphine, 405 Acetylnormethadol, 323 N-Allylnorpethidine, 233 8(3-Acyldihydrocodeinones, 52 3-Allylprodines (a and (3), 256 14-Acyl-4,5-epoxymotphinans, 58 'H-NMR and stereochemistry, 256 7-Acylhydromotphones, 128 X-ray crystallography, 256 Addiction, 4 N-Allylnormetazocine, 420 Adenylate cyclase, 6, 409, 413, 424,
    [Show full text]
  • Symposium Iv. Discriminative Stimulus Effects
    Life Sciences, Vol. 28, pp. 1571-1584 Pergamon Press Printed in the U.S.A. MINI - SYMPOSIUM IV. DISCRIMINATIVE STIMULUS EFFECTS OF NARCOTICS: EVIDENCE FOR MULTIPLE RECEPTOR-MEDIATED ACTIONS Seymore Herling and James H. Woods Departments of Pharmacology and Psychology University of Michigan Ann Arbor, Michigan q8109 The different pharmacological syndromes produced by morphine and related drugs in the chronic spinal dog led Martin and his colleagues (1,2) to suggest that these drugs exert their agonist actions 0y interacting with three distinct receptors (~,K, and e). Morphine was hypothesized to be an agonist for the p receptor, ketazocine (ketocyclazocine) was an agonist for the K receptor, and SKF-10,0q7 was an agonist for the ~ receptor. The effects of these three drugs in the chronic spinal dog were reversed by the narcotic antagonist, naltrexone, indicating that the effects of these drugs are narcotic agonist effects (I). In additlon to the different effects of these narcotics in the non- dependent chronic spinal dog, the effects of morphine, ketazocine, and SKF-IO,047 in several other behavioral and physiological preparations are consistent with the concept of multiple receptors. For example, while ketazocine and ethylketazocine, like morphine, produce analgesia, these compounds, unlike morphine, do not suppress signs of narcotic abstinence in the morphine-dependent rhesus monkey or morphine-dependent chronic spinal dog (1-5). Further, the characteristics of ketazocine withdrawal and antagonist- precipitated abstinence syndromes, although similar to those of cyclazocine, are quailtativeiy different from those of morphine (1,2). In rhesus monkeys, ketazocine, ethylketazocine, and SKF-10,047 maintain lever pressing at rates comparable to or below those maintained by saline, and well below response rates maintained by codeine or morphine (5,6), suggesting that the former set of drugs have limited reinforcing effect.
    [Show full text]
  • Psychoactive Natural Products: Overview of Recent Developments
    12 Ann Ist Super Sanità 2014 | Vol. 50, No. 1: 12-27 DOI: 10.4415/ANN_14_01_04 Psychoactive natural products: overview of recent developments István Ujváry REVIEWS iKem BT, Budapest, Hungary AND Abstract Natural psychoactive substances have fascinated the curious mind of shamans, artists, Key words ARTICLES scholars and laymen since antiquity. During the twentieth century, the chemical com- • ethnopharmacology position of the most important psychoactive drugs, that is opium, cannabis, coca and • mode of action “magic mushrooms”, has been fully elucidated. The mode of action of the principal in- • natural products gredients has also been deciphered at the molecular level. In the past two decades, the • psychopharmacology RIGINAL use of herbal drugs, such as kava, kratom and Salvia divinorum, began to spread beyond • toxicology O their traditional geographical and cultural boundaries. The aim of the present paper is to briefly summarize recent findings on the psychopharmacology of the most prominent psychoactive natural products. Current knowledge on a few lesser-known drugs, includ- ing bufotenine, glaucine, kava, betel, pituri, lettuce opium and kanna is also reviewed. In addition, selected cases of alleged natural (or semi-natural) products are also mentioned. O, mickle is the powerful grace that lies In herbs, plants, stones, and their true qualities William Shakespeare (Romeo and Juliet) INTRODUCTION Historical background of psychoactive natural During the past 200 years, there has been major pro- products research gress in our understanding of the composition and ef- The biochemical machinery of an organism generates fects of many psychoactive natural products, particular- many structurally related chemicals (Nature’s “combinato- ly those that have therapeutic uses.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,003,794 B2 Boyd Et Al
    USO08003794B2 (12) United States Patent (10) Patent No.: US 8,003,794 B2 Boyd et al. (45) Date of Patent: Aug. 23, 2011 (54) (S)-N-METHYLNALTREXONE 4.385,078 A 5/1983 Onda et al. 4.427,676 A 1, 1984 White et al. (75) Inventors: Thomas A. Boyd, Grandview, NY (US); 4,430,327 A 2, 1984 Frederickson et al. 4,452,775 A 6, 1984 Kent Howard Wagoner, Warwick, NY (US); 4,457.907. A 7/1984 Porter et al. Suketu P. Sanghvi, Kendall Park, NJ 4.462,839 A 7/1984 McGinley et al. (US); Christopher Verbicky, 4,466,968 A 8, 1984 Bernstein Broadalbin, NY (US); Stephen t St. A s 3. Miley al. Andruski, Clifton Park, NY (US) 4,556,552- - - A 12/1985 Porter2 et al.a. 4,606,909 A 8/1986 Bechgaard et al. (73) Assignee: Progenics Pharmaceuticals, Inc., 4,615,885 A 10/1986 Nakagame et al. Tarrytown, NY (US) 4,670.287. A 6/1987 Tsuji et al. 4.675, 189 A 6, 1987 Kent et al. (*) Notice: Subject to any disclaimer, the term of this 4,689,332 A 8/1987 McLaughlin et al. patent is extended or adjusted under 35 2.7868 A SE Se U.S.C. 154(b) by 184 days. 4,765,978 A 8/1988 Abidi et al. 4,806,556 A 2/1989 Portoghese (21) Appl. No.: 12/460,507 4,824,853. A 4, 1989 Walls et al. 4,836,212 A 6, 1989 Schmitt et al. (22) Filed: Jul. 20, 2009 4,837.214 A 6, 1989 Tanaka et al.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Comparison of the Behavioral Pharmacology of Phencyclidine to Related Compounds
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 1981 Comparison of the Behavioral Pharmacology of Phencyclidine to Related Compounds Kathleen T. Brady Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Medicine and Health Sciences Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/4377 This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. -,. , COMPARISON OF THE BEHAV IORAL PHARMACOLOGY OF PHENCYCLIOINE TO RELATED COMPOUNDS BY Kathleen T. Brady B.S., Fordham University, 1974 submitted in partial ful fillment of the requi rements for the Degree of Doctor of Phi l osophy in the Department of Pharmacology at the Medical Col lege of Virginia Virginia Commonwealth University Richmond, Vi rginia May , 1981 This thesis by Kathleen T. Brady is accepted in its present form as satisfying the thesis requirements for the degree of Doctor of Philosoph y. Date: A roved : .�.��!��.I.. Advisor, Chairman of Graduate Committee ' · . .mry. 7.).I!?'.' ... � 7/,fl • :: ::;.•• .I •••••.••• 1 y.!.. ·'it! I -l1J · �r:t?�.�.� &} · .. /:!.'1 ?J. !. �� ( . APPROVED: .. · .. Chairman, MCV Graduate Council, Dean. School of Basic· Sciences··· .. ii CURRICULilll VITAE ';.;'; vi ACKNOWLEDGEMENTS I would especially like to thank Dr . Robert Balster for his valuabl e encouragement, friendship and guidance throughout my graduate training. I feel very fortunate to have had the opportunity to be trai ned by and work with Dr.
    [Show full text]
  • FACT SHEET Acrylfentanyl
    FACT SHEET Acrylfentanyl May 2017 For more information, please contact: Dr. P. Blanckaert Coordinator Belgian Early Warning System Drugs Scientific Institute of Public Health National Focal Point on Drugs Jyliette Wytsmanstraat 14 B-1050 Brussels, Belgium Tel : 02/642 5408 [email protected] Science at the service of Public health, Food chain safety and Environment. The information in this message is exclusively meant for the EWS-network, and was sent to you, as a member of this network, in a confidential way. Therefore the information in this message may not be copied, transferred or made public without the prior permission of the WIV-ISP. The WIV-ISP takes responsibility for the editing of a press release, if considered as necessary in the framework of its mission. The information contained in this document is also available on the BEWSD-website (with corresponding pdf-files and analytical data). This part of the website is not accessible for the general public. A login can be requested by contacting [email protected]. © Scientific Institute of Public Health, Brussels 2011 This report may not be reproduced, published or distributed without the consent of the ISP | WIV. A. General information Recent sample in Belgium In the first half of May 2017, a death was reported in Belgium after the use of acrylfentanyl. The victim, male, presumably consumed a powder containing acrylfentanyl by sniffing, and was found dead at the scene, in the region of Ghent. It remains unclear whether the victim knowingly consumed acrylfentanyl. Several other powders and tablets were found at the scene, one of which was identified as N- ethylhexedrone, a cathinone of the stimulant category.
    [Show full text]
  • List of Psychoactive Drug Spirits for MD A-Methylfentanyl, Abilify
    List of Psychoactive Drug Spirits for MD A-Methylfentanyl, Abilify, abnormal basal ganglia function, abuse of medicines, Aceperone, Acepromazine, Aceprometazine, Acetildenafil, Aceto phenazine, Acetoxy Dipt, Acetyl morphone, Acetyl propionyl morphine, Acetyl psilocin, Activation syndrome, acute anxiety, acute hypertension, acute panic attacks, Adderall, Addictions to drugs, Addictions to medicines, Addictions to substances, Adrenorphin, Adverse effects of psychoactive drugs, adverse reactions to medicines, aggression, aggressive, aggressiveness, agitated depression, Agitation and restlessness, Aildenafil, Akuammine, alcohol abuse, alcohol addiction, alcohol withdrawl, alcohol-related brain damage, alcohol- related liver damage, alcohol mix with medicines for adverse reaction, Alcoholism, Alfetamine, Alimemazine, Alizapride, Alkyl nitrites, allergic breathing reactions to meds, choking to anaphallectic shock, & death; allergic skin reactions to meds, rash, itchyness, hives, welts, etc, Alletorphine, Almorexant, Alnespirone, Alpha Ethyltryptamine, Alpha Neoendorphin, alterations in brain hormones, alterations in mental status, altered consciousness, altered mind, Altoqualine, Alvimopan, Ambien, Amidephrine, Amidorphin, Amiflamine, Amisulpride, Amphetamines, Amyl nitrite, Anafranil, Analeptic, Anastrozole, Anazocine, Anilopam, Antabuse, anti anxiety meds, anti dopaminergic activity, anti seizure meds, Anti convulsants, Anti depressants, Anti emetics, Anti histamines, anti manic meds, anti parkinsonics, Anti psychotics, Anxiety disorders,
    [Show full text]